Chinese authorities fired a leading neuroscientist after a 6-year-old girl died in a gene-editing trial he led, and after that death went undisclosed in published research, state media reports.
Shanghai officials dismissed Zilong Qiu as deputy director of the Songjiang Research Institute, which is affiliated with Shanghai Jiao Tong University, following a government probe into the case, CBS News reported, citing Chinese state broadcaster CCTV.
The girl died in March from complications tied to the experimental gene therapy. She had been enrolled in a trial aimed at Snijders Blok-Campeau syndrome, a rare genetic disorder. A hospital ethics committee had approved the trial in January 2025 and shut it down after her death.
Qiu, the trial’s lead researcher, also drew a five-year ban from scientific projects and an entry in a database reserved for serious breaches of research integrity. Another researcher on his team was fired and handed the same five-year suspension. Several others with ties to the hospital were punished as well.
A joint investigation by Science and Retraction Watch, reported in July, found the child’s death was not laid out in the published research record. Qiu’s paper in the journal Nature, published Feb. 18, made no mention of the girl.
The girl’s parents paid more than $800,000 to fund the experiment. Official documents and the parents’ own accounts, as detailed in that July reporting, show the hospital let Qiu’s treatment move forward under a regulatory provision that did not require sign-off from national regulators.
After the child died, the hospital paid a modest fine to a local health authority. At that stage, Qiu faced no public sanction.
The girl’s father later described how the missing protections looked once the full picture emerged.
"Learning the reality of these missing safeguards has fundamentally changed how we now view the entire project,"
he told Science.
He added a second warning about the setup the family had trusted.
"We did not realize how unusual and dangerous many of the arrangements were."
Shanghai authorities said Qiu’s team failed to properly inform the hospital about possible safety issues from earlier tests on primates. That finding sat at the center of the statement CCTV carried on the dismissals and suspensions.
In plain terms, the hospital ethics panel green-lit a high-risk gene-editing effort in January. The patient died in March. The study ended. A major journal article still went out without accounting for the girl who had been treated. Months later, only after outside scrutiny and an official probe, came the firings, the multi-year bans, and the integrity black mark.
State media framed the penalties as a response to serious research-integrity failures. The public still does not have the hospital’s full name, the exact size of the “modest” fine, or a complete text of the Shanghai statement beyond the punishments described.
The episode lands in a country still living with the shadow of He Jiankui, the biophysicist who in 2018 secretly produced gene-edited babies. He was later sentenced to three years in prison.
That earlier case was about editing human embryos without legitimate ethical clearance and then hiding the work. This newer case is different in method, a sick child, a hospital trial pathway, parental funding, yet the pattern of delayed accountability is hard to miss. A child dies. Disclosure lags. Penalties arrive only after investigators and state media force the issue into the open.
Gene editing holds real medical promise for devastating rare diseases. It also demands ironclad consent rules, full safety disclosure, and honest publication. When a regulatory side door lets a trial skip national review, when primate risk signals do not reach the hospital cleanly, and when a death never appears in the paper tied to the work, families are left carrying both the grief and the bill.
Here the bill topped $800,000. The grief is permanent. The institutional answer, for a long stretch after the March death, was a modest fine and silence about the lead scientist, until the probe and the Friday announcement from Shanghai.
AFP sought comment from Qiu. The available reporting does not record a reply.
China wants to lead in biotech. Leadership that skips safeguards, buries bad outcomes, and bills desperate parents is not leadership. It is a warning label written in a child’s name.